Abstract
24P Efficacy and safety of 1st generation EGFR TKI retreatment in EGFR mutation-positive, T790M-negative patients previously treated with 1st or 2nd generation EGFR TKI and cytotoxic chemotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have